ATYR
aTYR PHARMA INCCompany Information
- Company Name
- aTYR PHARMA INC
- CIK
- CIK0001339970
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ATYR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ATYR
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-27
- Last sale
- 2026-02-04
- Shares purchased (TTM)
- 417,999
- Shares sold (TTM)
- 6,421
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 35,402,159
- Shares outstanding
- 98,069,915
- Ownership
- 36.10%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- 5.68%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 16 | 10 | 11 | 6 | 17 | 10 | 11 | 11 | 7 | 7 | 23 | 10 | ||||||
| Available For Sale Securities Debt Securities Current | 41 | 57 | 68 | 84 | 63 | 66 | 61 | 55 | 72 | 78 | 76 | 92 | ||||||
| Other Receivables Net Current | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Prepaid Expense Current | 1 | 1 | 1 | 2 | 7 | 6 | 8 | 8 | 10 | 10 | 2 | 3 | ||||||
| Assets Current | 58 | 68 | 80 | 93 | 87 | 83 | 82 | 76 | 90 | 97 | 103 | 107 | ||||||
| Restricted Cash Noncurrent | 1 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Property Plant And Equipment Net | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | ||||||
| Operating Lease Right Of Use Asset | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | ||||||
| Finance Lease Right Of Use Asset | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 70 | 80 | 93 | 107 | 102 | 97 | 97 | 92 | 106 | 113 | 121 | 125 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 3 | 4 | 4 | 4 | 2 | 4 | 4 | 1 | 5 | 4 | 2 | ||||||
| Accrued Liabilities Current | 7 | 7 | 10 | 10 | 10 | 8 | 9 | 9 | 9 | 10 | 12 | 10 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finance Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Liabilities Current | 11 | 12 | 15 | 16 | 16 | 11 | 15 | 14 | 12 | 16 | 16 | 13 | ||||||
| Operating Lease Liability Noncurrent | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 13 | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 676 | 675 | 674 | 672 | 641 | 622 | 602 | 582 | 582 | 568 | 559 | 552 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -627 | -617 | -606 | -592 | -566 | -547 | -532 | -517 | -500 | -484 | -468 | -453 | ||||||
| Stockholders Equity | 49 | 58 | 67 | 80 | 75 | 75 | 70 | 65 | 82 | 84 | 90 | 98 | ||||||
| Minority Interest | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Liabilities And Stockholders Equity | 70 | 80 | 93 | 107 | 102 | 97 | 97 | 92 | 106 | 113 | 121 | 125 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 340 | 170 | 170 | 170 | 170 | 170 | 170 | 170 | 170 | 170 | 170 | 170 | ||||||
| Common Stock Shares Issued | 98 | 98 | 98 | 98 | 93 | 89 | 84 | 76 | 76 | 68 | 63 | 59 | ||||||
| Shares Outstanding | 98 | 98 | 98 | 98 | 93 | 89 | 84 | 76 | 76 | 68 | 63 | 59 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialaTYR PHARMA INC (ATYR) — SEC Financial Statements & Analysis
aTYR PHARMA INC (ATYR) is a biological products, (no diagnostic substances) company, incorporated in DE. aTYR PHARMA INC trades on Nasdaq as: ATYR. aTYR PHARMA INC (ATYR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, aTYR PHARMA INC carries a market cap of $58.55M, a P/E ratio of -0.96x, a P/B ratio of 1.20x, a P/S ratio of 308.15x, an enterprise value of $42.94M, and an EV/EBITDA multiple of -0.68x. On profitability, it posts an operating margin of -33609.47%, a net margin of -32005.79%, a Return on Equity (ROE) of -98.52%, a Return on Assets (ROA) of -70.97%, and a Return on Invested Capital (ROIC) of -139.15%. Per share, it reports EPS of $-0.62, diluted EPS of $-0.62, free cash flow per share of $-0.56, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -19.15% year-over-year, net income growth of -8.75% year-over-year, and EPS growth of -16.15% year-over-year. On the balance sheet, it maintains a current ratio of 5.12x, a quick ratio of 5.08x, working capital of $46.97M, a debt-to-equity ratio of 0.23x, a debt ratio of 0.16, free cash flow of $-54.82M (TTM), and net debt of $-15.61M. Figures sourced from SEC EDGAR.
- Market Cap
- $58.55M
- P/E TTM
- -0.96x
- EPS TTM
- $-0.62
- P/B TTM
- 1.20x
- ROE TTM
- -98.52%
- ROA TTM
- -70.97%
- Debt To Equity
- 0.23x
- Free Cash Flow TTM
- $-54.82M
- Net Revenue TTM Growth 1Y
- -19.15%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is aTYR PHARMA INC in?
aTYR PHARMA INC (ATYR) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ATYR trade on?
aTYR PHARMA INC (ATYR) trades on the Nasdaq.
Where is aTYR PHARMA INC incorporated?
aTYR PHARMA INC is incorporated in DE.
When was aTYR PHARMA INC (ATYR)'s most recent SEC filing?
aTYR PHARMA INC (ATYR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is ATYR's market cap?
aTYR PHARMA INC (ATYR) has a market capitalization of $58.55M as of 2026-06-30.
What is ATYR's EPS (earnings per share)?
aTYR PHARMA INC (ATYR)'s trailing twelve month EPS is $-0.62 as of 2026-06-30.
What is ATYR's ROE (return on equity)?
aTYR PHARMA INC (ATYR)'s trailing twelve month Return on Equity (ROE) is -98.52% as of 2026-06-30.
What is ATYR's ROA (return on assets)?
aTYR PHARMA INC (ATYR)'s trailing twelve month Return on Assets (ROA) is -70.97% as of 2026-06-30.
What is ATYR's ROIC (return on invested capital)?
aTYR PHARMA INC (ATYR)'s trailing twelve month Return on Invested Capital (ROIC) is -139.15% as of 2026-06-30.
What is ATYR's EV/EBITDA?
aTYR PHARMA INC (ATYR)'s trailing twelve month EV/EBITDA is -0.68x as of 2026-06-30.